Sutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed as "Outperform" by Wedbush

Sutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed as "Outperform" by Wedbush

Wedbush reiterated an "outperform" rating and set a $60.00 price target on shares of Sutro Biopharma in a report on Thursday.

Sutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed as “Outperform” by Wedbush

Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a report released on Thursday, Benzinga reports. They presently have a $60.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 441.52% from the stock’s previous close. A number of other […]